David Blakey | Chief Scientific Officer
MiNA Therapeutics

David Blakey, Chief Scientific Officer, MiNA Therapeutics

David Blakey has a degree in Biochemistry from Oxford University, a PhD from London University and then worked as a Post Doc at the ICRF in London. In 1987 he joined AstraZeneca where he championed the company’s move into therapeutic antibodies. He was appointed Chief Scientist in Oncology in 2008 and in his last 5-6 years at AstraZeneca he led a global cross therapy area team on oligonucleotide-based therapies. In October 2015, continuing his career in Oligonucleotide Therapeutics, he joined MiNA Therapeutics as their CSO and leads research on their small activating RNA oligonucleotide platform.


Conference Day 1 - Tuesday 31st March 2020 @ 15:40

Panel: Leading approaches for drug discovery in the mRNA space

Conference Day 2 - Wednesday 1st April 2020 @ 12:00

Small activating RNAs as a novel approach for immunotherapy

  • Small activating RNAs can be designed to a wide range of targets to activate gene transcription
  • MiNA Therapeutics’lead saRNA to CEBPA has demonstrated proofof concept in the clinic
  • Novel saRNAs have been designed to specifically up-regulated immune targets for cancer immunotherapy
last published: 04/Jun/20 08:25 GMT

back to speakers